{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:22:36Z","timestamp":1788517356688,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Projekt DEAL"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The aim of the present study was to analyze copy number variations (CNV) of multiple oncogenes and tumor suppressor genes in genomic DNA from primary tumor tissue, lymph node metastasis and cell-free DNA (cfDNA) from serum of 72 urothelial carcinoma of bladder (UCB) patients treated with radical cystectomy (RC), using multiplex ligation-dependent probe amplification (MLPA). We hypothesized that primary tumor and lymph node metastasis show similar CNV profiles, and CNV are more present in lymph node metastasis compared to primary tumor tissue. Samples from 43 (59.7%) patients could be analyzed. In total, 35 (83%), 26 (68%) and 8 (42%) patients had CNV in primary tumor, serum and lymph node metastasis, respectively. MYC, CCND1, ERBB2 and CCNE1 displayed the most frequent amplifications. In particular, CNV in ERBB2 was associated with aggressive tumor characteristics. CNV in both ERBB2 and TOP2A were risk factors for disease recurrence. The current findings show that CNV are present in various oncogenes and tumor suppressor genes in genomic DNA from primary tumor, lymph node metastasis and cfDNA from serum. CNV were more present in genomic DNA from primary tumor tissue compared to cfDNA from serum and genomic DNA from lymph node metastasis. Patients with CNV in ERBB2 and TOP2A are at increased risk for disease recurrence following RC. Further studies are necessary to validate, whether these genes may represent promising candidates for targeted-therapy.<\/jats:p>","DOI":"10.1038\/s41598-020-75869-x","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T11:52:15Z","timestamp":1607514735000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy"],"prefix":"10.1038","volume":"10","author":[{"given":"Armin","family":"Soave","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Kluwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Gild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte W.","family":"Vetterlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margit","family":"Fisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian P.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Dahlem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Minner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Pantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Steinbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Schwarzenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,9]]},"reference":[{"key":"75869_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 69, 7\u201334. https:\/\/doi.org\/10.3322\/caac.21551 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"75869_CR2","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.eururo.2013.11.046","volume":"65","author":"JA Witjes","year":"2014","unstructured":"Witjes, J. A. et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2013 guidelines. Eur. Urol. 65, 778\u2013792. https:\/\/doi.org\/10.1016\/j.eururo.2013.11.046 (2014).","journal-title":"Eur. Urol."},{"key":"75869_CR3","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","volume":"19","author":"JP Stein","year":"2001","unstructured":"Stein, J. P. et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1054 patients. J. Clin. Oncol. 19, 666\u2013675 (2001).","journal-title":"J. Clin. Oncol."},{"key":"75869_CR4","doi-asserted-by":"publisher","first-page":"E30","DOI":"10.1111\/j.1464-410X.2012.11433.x","volume":"111","author":"M Rink","year":"2013","unstructured":"Rink, M. et al. Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. BJU Int. 111, E30-36. https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11433.x (2013).","journal-title":"BJU Int."},{"key":"75869_CR5","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.21037\/tau.2017.09.16","volume":"6","author":"S Riethdorf","year":"2017","unstructured":"Riethdorf, S., Soave, A. & Rink, M. The current status and clinical value of circulating tumor cells and circulating cell-free tumor DNA in bladder cancer. Transl. Androl. Urol. 6, 1090\u20131110. https:\/\/doi.org\/10.21037\/tau.2017.09.16 (2017).","journal-title":"Transl. Androl. Urol."},{"key":"75869_CR6","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171, 540-556.e525. https:\/\/doi.org\/10.1016\/j.cell.2017.09.007 (2017).","journal-title":"Cell"},{"key":"75869_CR7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nrg3871","volume":"16","author":"M Zarrei","year":"2015","unstructured":"Zarrei, M., MacDonald, J. R., Merico, D. & Scherer, S. W. A copy number variation map of the human genome. Nat. Rev. Genet. 16, 172\u2013183. https:\/\/doi.org\/10.1038\/nrg3871 (2015).","journal-title":"Nat. Rev. Genet."},{"key":"75869_CR8","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1097\/MOP.0000000000000142","volume":"26","author":"FM Mikhail","year":"2014","unstructured":"Mikhail, F. M. Copy number variations and human genetic disease. Curr. Opin. Pediatr. 26, 646\u2013652. https:\/\/doi.org\/10.1097\/MOP.0000000000000142 (2014).","journal-title":"Curr. Opin. Pediatr."},{"key":"75869_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3390\/ijms17030271","volume":"17","author":"D Conconi","year":"2016","unstructured":"Conconi, D. et al. Using copy number alterations to identify new therapeutic targets for bladder carcinoma. Int. J. Mol. Sci. 17, 271. https:\/\/doi.org\/10.3390\/ijms17030271 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"75869_CR10","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1158\/1078-0432.CCR-12-3768","volume":"19","author":"H Gevensleben","year":"2013","unstructured":"Gevensleben, H. et al. Noninvasive detection of HER2 amplification with plasma DNA digital PCR. Clin. Cancer Res. 19, 3276\u20133284. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3768 (2013).","journal-title":"Clin. Cancer Res."},{"key":"75869_CR11","doi-asserted-by":"publisher","first-page":"8604","DOI":"10.1021\/ac202028g","volume":"83","author":"BJ Hindson","year":"2011","unstructured":"Hindson, B. J. et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal. Chem. 83, 8604\u20138610. https:\/\/doi.org\/10.1021\/ac202028g (2011).","journal-title":"Anal. Chem."},{"key":"75869_CR12","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1586\/14737159.2015.1053467","volume":"15","author":"JY Hehir-Kwa","year":"2015","unstructured":"Hehir-Kwa, J. Y., Pfundt, R. & Veltman, J. A. Exome sequencing and whole genome sequencing for the detection of copy number variation. Exp. Rev. Mol. Diagn. 15, 1023\u20131032. https:\/\/doi.org\/10.1586\/14737159.2015.1053467 (2015).","journal-title":"Exp. Rev. Mol. Diagn."},{"key":"75869_CR13","doi-asserted-by":"publisher","first-page":"e0143006","DOI":"10.1371\/journal.pone.0143006","volume":"10","author":"O Kondrashova","year":"2015","unstructured":"Kondrashova, O. et al. High-throughput amplicon-based copy number detection of 11 genes in formalin-fixed paraffin-embedded ovarian tumour samples by MLPA-seq. PLoS ONE 10, e0143006. https:\/\/doi.org\/10.1371\/journal.pone.0143006 (2015).","journal-title":"PLoS ONE"},{"key":"75869_CR14","doi-asserted-by":"publisher","first-page":"e0180647","DOI":"10.1371\/journal.pone.0180647","volume":"12","author":"B Molparia","year":"2017","unstructured":"Molparia, B., Nichani, E. & Torkamani, A. Assessment of circulating copy number variant detection for cancer screening. PLoS ONE 12, e0180647. https:\/\/doi.org\/10.1371\/journal.pone.0180647 (2017).","journal-title":"PLoS ONE"},{"key":"75869_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2015.07.002","volume":"90","author":"S Xia","year":"2015","unstructured":"Xia, S. et al. Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls. Lung Cancer 90, 78\u201384. https:\/\/doi.org\/10.1016\/j.lungcan.2015.07.002 (2015).","journal-title":"Lung Cancer"},{"key":"75869_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-018-2543-9","author":"M Rink","year":"2018","unstructured":"Rink, M., Schwarzenbach, H., Riethdorf, S. & Soave, A. The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladder. World J. Urol. https:\/\/doi.org\/10.1007\/s00345-018-2543-9 (2018).","journal-title":"World J. Urol."},{"key":"75869_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.21037\/tau.2018.11.05","volume":"8","author":"M Rink","year":"2019","unstructured":"Rink, M., Schwarzenbach, H., Vetterlein, M. W., Riethdorf, S. & Soave, A. The current role of circulating biomarkers in non-muscle invasive bladder cancer. Transl. Androl. Urol. 8, 61\u201375. https:\/\/doi.org\/10.21037\/tau.2018.11.05 (2019).","journal-title":"Transl. Androl. Urol."},{"key":"75869_CR18","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/nrc3066","volume":"11","author":"H Schwarzenbach","year":"2011","unstructured":"Schwarzenbach, H., Hoon, D. S. & Pantel, K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 11, 426\u2013437. https:\/\/doi.org\/10.1038\/nrc3066 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"75869_CR19","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1373\/clinchem.2007.099333","volume":"54","author":"I Muller","year":"2008","unstructured":"Muller, I. et al. Identification of loss of heterozygosity on circulating free DNA in peripheral blood of prostate cancer patients: potential and technical improvements. Clin. Chem. 54, 688\u2013696 (2008).","journal-title":"Clin. Chem."},{"key":"75869_CR20","doi-asserted-by":"publisher","first-page":"56398","DOI":"10.18632\/oncotarget.17657","volume":"8","author":"A Soave","year":"2017","unstructured":"Soave, A. et al. Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: A prospective study. Oncotarget 8, 56398\u201356407. https:\/\/doi.org\/10.18632\/oncotarget.17657 (2017).","journal-title":"Oncotarget"},{"key":"75869_CR21","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00432-010-0941-5","volume":"137","author":"H Schwarzenbach","year":"2011","unstructured":"Schwarzenbach, H., Chun, F. K., Isbarn, H., Huland, H. & Pantel, K. Genomic profiling of cell-free DNA in blood and bone marrow of prostate cancer patients. J. Cancer Res. Clin. Oncol. 137, 811\u2013819. https:\/\/doi.org\/10.1007\/s00432-010-0941-5 (2011).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"75869_CR22","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/978-1-4939-8973-7_6","volume":"85\u201393","author":"H Schwarzenbach","year":"1909","unstructured":"Schwarzenbach, H. Copy number variation analysis on cell-free serum DNA. Methods Mol. Biol. 85\u201393, 2019. https:\/\/doi.org\/10.1007\/978-1-4939-8973-7_6 (1909).","journal-title":"Methods Mol. Biol."},{"key":"75869_CR23","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.urolonc.2010.04.008","volume":"28","author":"DJ McConkey","year":"2010","unstructured":"McConkey, D. J. et al. Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. Urol Oncol 28, 429\u2013440. https:\/\/doi.org\/10.1016\/j.urolonc.2010.04.008 (2010).","journal-title":"Urol Oncol"},{"key":"75869_CR24","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","volume":"32","author":"LA Diaz Jr","year":"2014","unstructured":"Diaz, L. A. Jr. & Bardelli, A. Liquid biopsies: Genotyping circulating tumor DNA. J. Clin. Oncol. 32, 579\u2013586. https:\/\/doi.org\/10.1200\/JCO.2012.45.2011 (2014).","journal-title":"J. Clin. Oncol."},{"key":"75869_CR25","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/bju.13782","volume":"119","author":"A Soave","year":"2017","unstructured":"Soave, A. et al. Detection and oncological effect of circulating tumour cells in patients with variant urothelial carcinoma histology treated with radical cystectomy. BJU Int. 119, 854\u2013861. https:\/\/doi.org\/10.1111\/bju.13782 (2017).","journal-title":"BJU Int."},{"key":"75869_CR26","first-page":"753","volume":"151","author":"U Wagner","year":"1997","unstructured":"Wagner, U. et al. Chromosome 8p deletions are associated with invasive tumor growth in urinary bladder cancer. Am. J. Pathol. 151, 753\u2013759 (1997).","journal-title":"Am. J. Pathol."},{"key":"75869_CR27","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.urology.2009.04.080","volume":"75","author":"E Prat","year":"2010","unstructured":"Prat, E. et al. Comparative genomic hybridization analysis reveals new different subgroups in early-stage bladder tumors. Urology 75, 347\u2013355. https:\/\/doi.org\/10.1016\/j.urology.2009.04.080 (2010).","journal-title":"Urology"},{"key":"75869_CR28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","volume":"149","author":"CV Dang","year":"2012","unstructured":"Dang, C. V. MYC on the path to cancer. Cell 149, 22\u201335. https:\/\/doi.org\/10.1016\/j.cell.2012.03.003 (2012).","journal-title":"Cell"},{"key":"75869_CR29","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/sj.bjc.6600531","volume":"87","author":"AD Watters","year":"2002","unstructured":"Watters, A. D. et al. Genetic aberrations of c-myc and CCND1 in the development of invasive bladder cancer. Br. J. Cancer 87, 654\u2013658. https:\/\/doi.org\/10.1038\/sj.bjc.6600531 (2002).","journal-title":"Br. J. Cancer"},{"key":"75869_CR30","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.4161\/cc.3.9.1145","volume":"3","author":"RC Sears","year":"2004","unstructured":"Sears, R. C. The life cycle of C-myc: from synthesis to degradation. Cell Cycle 3, 1133\u20131137 (2004).","journal-title":"Cell Cycle"},{"key":"75869_CR31","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/ijc.21253","volume":"117","author":"B Zaharieva","year":"2005","unstructured":"Zaharieva, B. et al. High-throughput tissue microarray analysis of CMYC amplificationin urinary bladder cancer. Int. J. Cancer 117, 952\u2013956. https:\/\/doi.org\/10.1002\/ijc.21253 (2005).","journal-title":"Int. J. Cancer"},{"key":"75869_CR32","doi-asserted-by":"publisher","first-page":"43791","DOI":"10.18632\/oncotarget.6101","volume":"6","author":"Y Gao","year":"2015","unstructured":"Gao, Y. et al. Beyond proliferation: KLF5 promotes angiogenesis of bladder cancer through directly regulating VEGFA transcription. Oncotarget 6, 43791\u201343805. https:\/\/doi.org\/10.18632\/oncotarget.6101 (2015).","journal-title":"Oncotarget"},{"key":"75869_CR33","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.18632\/oncotarget.6380","volume":"7","author":"S Wu","year":"2016","unstructured":"Wu, S. et al. Novel variants in MLL confer to bladder cancer recurrence identified by whole-exome sequencing. Oncotarget 7, 2629\u20132645. https:\/\/doi.org\/10.18632\/oncotarget.6380 (2016).","journal-title":"Oncotarget"},{"key":"75869_CR34","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/j.biocel.2003.12.005","volume":"36","author":"T Moroy","year":"2004","unstructured":"Moroy, T. & Geisen, C. Cyclin E. Int. J. Biochem. Cell Biol. 36, 1424\u20131439. https:\/\/doi.org\/10.1016\/j.biocel.2003.12.005 (2004).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"75869_CR35","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1038\/emm.2016.120","volume":"49","author":"BN Song","year":"2017","unstructured":"Song, B. N., Kim, S. K. & Chu, I. S. Bioinformatic identification of prognostic signature defined by copy number alteration and expression of CCNE1 in non-muscle invasive bladder cancer. Exp. Mol. Med. 49, e282. https:\/\/doi.org\/10.1038\/emm.2016.120 (2017).","journal-title":"Exp. Mol. Med."},{"key":"75869_CR36","first-page":"2872","volume":"63","author":"JA Veltman","year":"2003","unstructured":"Veltman, J. A. et al. Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Can. Res. 63, 2872\u20132880 (2003).","journal-title":"Can. Res."},{"key":"75869_CR37","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s00109-016-1475-3","volume":"94","author":"S Qie","year":"2016","unstructured":"Qie, S. & Diehl, J. A. Cyclin D1, cancer progression, and opportunities in cancer treatment. J. Mol. Med. (Berl) 94, 1313\u20131326. https:\/\/doi.org\/10.1007\/s00109-016-1475-3 (2016).","journal-title":"J. Mol. Med. (Berl)"},{"key":"75869_CR38","doi-asserted-by":"publisher","first-page":"11369","DOI":"10.1073\/pnas.172285799","volume":"99","author":"X Huang","year":"2002","unstructured":"Huang, X., Gollin, S. M., Raja, S. & Godfrey, T. E. High-resolution mapping of the 11q13 amplicon and identification of a gene, TAOS1, that is amplified and overexpressed in oral cancer cells. Proc. Natl. Acad. Sci. U.S.A. 99, 11369\u201311374. https:\/\/doi.org\/10.1073\/pnas.172285799 (2002).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"75869_CR39","doi-asserted-by":"publisher","first-page":"e60927","DOI":"10.1371\/journal.pone.0060927","volume":"8","author":"Y Chekaluk","year":"2013","unstructured":"Chekaluk, Y. et al. Identification of nine genomic regions of amplification in urothelial carcinoma, correlation with stage, and potential prognostic and therapeutic value. PLoS ONE 8, e60927. https:\/\/doi.org\/10.1371\/journal.pone.0060927 (2013).","journal-title":"PLoS ONE"},{"key":"75869_CR40","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3389\/fphar.2015.00283","volume":"6","author":"A Appert-Collin","year":"2015","unstructured":"Appert-Collin, A., Hubert, P., Cremel, G. & Bennasroune, A. Role of ErbB receptors in cancer cell migration and invasion. Front. Pharmacol. 6, 283. https:\/\/doi.org\/10.3389\/fphar.2015.00283 (2015).","journal-title":"Front. Pharmacol."},{"key":"75869_CR41","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/cyto.990210109","volume":"21","author":"G Sauter","year":"1995","unstructured":"Sauter, G., Moch, H., Gasser, T. C., Mihatsch, M. J. & Waldman, F. M. Heterogeneity of chromosome-17 and Erbb-2 gene copy number in primary and metastatic bladder-cancer. Cytometry 21, 40\u201346. https:\/\/doi.org\/10.1002\/cyto.990210109 (1995).","journal-title":"Cytometry"},{"key":"75869_CR42","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ctrv.2006.10.001","volume":"33","author":"MS Mano","year":"2007","unstructured":"Mano, M. S., Rosa, D. D., De Azambuja, E., Ismael, G. F. & Durbecq, V. The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours. Cancer Treat. Rev. 33, 64\u201377. https:\/\/doi.org\/10.1016\/j.ctrv.2006.10.001 (2007).","journal-title":"Cancer Treat. Rev."},{"key":"75869_CR43","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/ijc.11477","volume":"107","author":"R Simon","year":"2003","unstructured":"Simon, R. et al. HER-2 and TOP2A coamplification in urinary bladder cancer. Int. J. Cancer 107, 764\u2013772. https:\/\/doi.org\/10.1002\/ijc.11477 (2003).","journal-title":"Int. J. Cancer"},{"key":"75869_CR44","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.molonc.2009.11.001","volume":"4","author":"KV Nielsen","year":"2010","unstructured":"Nielsen, K. V. et al. Aberrations of ERBB2 and TOP2A genes in breast cancer. Mol. Oncol. 4, 161\u2013168. https:\/\/doi.org\/10.1016\/j.molonc.2009.11.001 (2010).","journal-title":"Mol. Oncol."},{"key":"75869_CR45","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s00345-015-1557-9","volume":"33","author":"W Ding","year":"2015","unstructured":"Ding, W. et al. Human epidermal growth factor receptor 2: a significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups. World J. Urol. 33, 1951\u20131957. https:\/\/doi.org\/10.1007\/s00345-015-1557-9 (2015).","journal-title":"World J. Urol."},{"key":"75869_CR46","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.anndiagpath.2019.01.002","volume":"39","author":"AE Abdelrahman","year":"2019","unstructured":"Abdelrahman, A. E. et al. Fatty acid synthase, Her2\/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer. Ann. Diagn. Pathol. 39, 42\u201352. https:\/\/doi.org\/10.1016\/j.anndiagpath.2019.01.002 (2019).","journal-title":"Ann. Diagn. Pathol."},{"issue":"1516","key":"75869_CR47","doi-asserted-by":"publisher","first-page":"e1519","DOI":"10.1016\/j.urology.2009.08.055","volume":"75","author":"EJ Kim","year":"2010","unstructured":"Kim, E. J. et al. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer. Urology 75(1516), e1519\u2013e1513. https:\/\/doi.org\/10.1016\/j.urology.2009.08.055 (2010).","journal-title":"Urology"},{"key":"75869_CR48","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ajur.2020.05.011","volume":"7","author":"A Tripathi","year":"2020","unstructured":"Tripathi, A. & Gupta, S. Androgen receptor in bladder cancer: A promising therapeutic target. Asian J. Urol. 7, 284\u2013290. https:\/\/doi.org\/10.1016\/j.ajur.2020.05.011 (2020).","journal-title":"Asian J. Urol."},{"key":"75869_CR49","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1097\/00000478-199812000-00001","volume":"22","author":"JI Epstein","year":"1998","unstructured":"Epstein, J. I., Amin, M. B., Reuter, V. R., Mostofi, F. K. & Committee, T. B. C. C. The World Health Organization\/International Society of Urological pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am. J. Surg. Pathol. 22, 1435\u20131448 (1998).","journal-title":"Am. J. Surg. Pathol."},{"key":"75869_CR50","doi-asserted-by":"publisher","first-page":"6533","DOI":"10.1200\/jco.2005.05.516","volume":"23","author":"Y Lotan","year":"2005","unstructured":"Lotan, Y. et al. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J. Clin. Oncol. 23, 6533\u20136539. https:\/\/doi.org\/10.1200\/jco.2005.05.516 (2005).","journal-title":"J. Clin. Oncol."},{"key":"75869_CR51","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.urology.2004.10.048","volume":"65","author":"SK Hong","year":"2005","unstructured":"Hong, S. K., Kwak, C., Jeon, H. G., Lee, E. & Lee, S. E. Do vascular, lymphatic, and perineural invasion have prognostic implications for bladder cancer after radical cystectomy?. Urology 65, 697\u2013702. https:\/\/doi.org\/10.1016\/j.urology.2004.10.048 (2005).","journal-title":"Urology"},{"key":"75869_CR52","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1016\/j.juro.2010.02.021","volume":"183","author":"G Novara","year":"2010","unstructured":"Novara, G. et al. Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: A multicenter study of more than 4,400 patients. J. Urol. 183, 2165\u20132170. https:\/\/doi.org\/10.1016\/j.juro.2010.02.021 (2010).","journal-title":"J. Urol."},{"key":"75869_CR53","unstructured":"Eble, J., Sauter, G., Epstein, J. I. & Sesterhenn, I. A. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. World Health Organization Classification of Tumours Lyon: IARCC Press (2004)."},{"key":"75869_CR54","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.juro.2013.05.034","volume":"190","author":"HM Bruins","year":"2013","unstructured":"Bruins, H. M. et al. Incidental prostate cancer in patients with bladder urothelial carcinoma: Comprehensive analysis of 1,476 radical cystoprostatectomy specimens. J. Urol. 190, 1704\u20131709. https:\/\/doi.org\/10.1016\/j.juro.2013.05.034 (2013).","journal-title":"J. Urol."},{"key":"75869_CR55","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.eururo.2011.12.055","volume":"61","author":"M Rink","year":"2012","unstructured":"Rink, M. et al. Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. Eur. Urol. 61, 854\u2013855. https:\/\/doi.org\/10.1016\/j.eururo.2011.12.055 (2012).","journal-title":"Eur. Urol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75869-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75869-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75869-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:43:22Z","timestamp":1670373802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75869-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,9]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["75869"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-75869-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,9]]},"assertion":[{"value":"8 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21562"}}